MCLEAN, Va., April 19, 2018 -- Freddie Mac (OTCQB:FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing average mortgage rates jumping across the board.
|
|||||
News Facts
- 30-year fixed-rate mortgage (FRM) averaged 4.47 percent with an average 0.5 point for the week ending April 19, 2018, up from last week when it averaged 4.42 percent. A year ago at this time, the 30-year FRM averaged 3.97 percent.
- 15-year FRM this week averaged 3.94 percent with an average 0.4 point, up from last week when it averaged 3.87 percent. A year ago at this time, the 15-year FRM averaged 3.23 percent.
- 5-year Treasury-indexed hybrid adjustable-rate mortgage (ARM) averaged 3.67 percent this week with an average 0.3 point, up from last week when it averaged 3.61. A year ago at this time, the 5-year ARM averaged 3.10 percent.
Average commitment rates should be reported along with average fees and points to reflect the total upfront cost of obtaining the mortgage. Visit the following link for the Definitions. Borrowers may still pay closing costs which are not included in the survey.
Quote
Attributed to Len Kiefer, Deputy Chief Economist.
“Treasury yields rose ahead of the release of the Fed’s Beige Book and speeches from New York Fed President William Dudley and Fed Governor Randal Quarles. According to the Beige Book, economic activity in March and early April continued to expand at a moderate pace, however there is concern from various industries surrounding tariffs. Following Treasurys, mortgage rates soared. The U.S. weekly average 30-year fixed mortgage rate rose 5 basis points to 4.47 percent in this week’s survey, its highest level since January of 2014 and the largest weekly increase since February of this year.
“It is important to note that the weekly rate we report is an average and the actual rate obtained by a borrower may be different. In our April Insight, we found that by shopping more than one mortgage lender, consumers are more likely to get a better interest rate and save money in both the short and long term. With lower monthly payments and lower fixed fees, the loan will be more affordable and thus safer, and consumers may keep hundreds or thousands of dollars more in their pocket.”
Freddie Mac makes home possible for millions of families and individuals by providing mortgage capital to lenders. Since our creation by Congress in 1970, we’ve made housing more accessible and affordable for homebuyers and renters in communities nationwide. We are building a better housing finance system for homebuyers, renters, lenders and taxpayers. Learn more at FreddieMac.com, Twitter @FreddieMac and Freddie Mac’s blog FreddieMac.com/blog.
A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/67fa74a1-6ba4-4f3b-aaca-a675813acbbc
MEDIA CONTACT: Paul Frommelt
703-903-3999
[email protected]


TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 



